NeuroSearch to present at Cowen's 27th Annual US Health Care Conference in Boston


--------------------------------------------------------------------------------
| NeuroSearch to present at Cowen's 27th Annual US Health Care Conference in   |
| Boston                                                                       |
--------------------------------------------------------------------------------
| NeuroSearch (NEUR) will present at Cowen's 27th Annual Health Care           |
| Conference to be held from Monday 12 to Thursday 15 March at The Boston      |
| Marriott Copley Place Hotel, 110 Huntington Avenue, Boston, USA.             |
| The presentation will be held by Flemming Pedersen, CEO, and is scheduled    |
| for                                                                          |
| Tuesday 13 March at 3:15 - 3:50 pm                                           |
| The presentation will be followed by a breakout session at 4:00 - 4:35 pm.   |
| A PowerPoint version of the presentation will be accessible on our website   |
| www.neurosearch.com just prior to the presentation at the conference.        |
--------------------------------------------------------------------------------
| Contact:  | Hanne Leth Hillman, Vice President, Director of Investor         |
|           | Relations and Corporate Communications                           |
|           | Phone: +45 4460 8212 or +45 4017 5103                            |
--------------------------------------------------------------------------------
| NeuroSearch is a Scandinavian biopharmaceutical company listed on the        |
| Copenhagen Stock Exchange (NEUR). Our core business covers the development   |
| of novel drugs, based on a broad and well-established drug discovery         |
| platform focusing on ion channels and transporters. A substantial part of    |
| the company's activities are partner financed through a broad alliance with  |
| GlaxoSmithKline (GSK) and collaborations with among others Abbott and        |
| Astellas. Nine drug programmes are in clinical development: ACR16 for the    |
| treatment of Huntington's disease (under preparation for Phase III),         |
| tesofensine for the treatment of obesity/type 2 diabetes (Phase II), NS2359  |
| for the treatment of depression (Phase II) and ADHD (Phase II) in            |
| partnership with GSK, NS1209 for the treatment of epilepsy and pain (Phase   |
| II), ABT-894 for the treatment of ADHD (Phase II) and neuropathic pain       |
| (Phase I) in partnership with Abbott, ACR16 for the treatment of             |
| schizophrenia (Phase I) in partnership with Astellas, and ACR325 for the     |
| treatment of psychoses and bipolar disorder (Phase I). In addition,          |
| NeuroSearch has a broad portfolio of preclinical drug candidates and has     |
| equity interests in several biotech companies.                               |
--------------------------------------------------------------------------------

Attachments

presse 02-07 - presentation at cowen hc conf boston_uk.pdf